Pulmonx Corporation (LUNG)
Largest Insider Buys in Sector
LUNG Stock Price History Chart
LUNG Stock Performance
About Pulmonx Corporation
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based …
Insider Activity of Pulmonx Corporation
Over the last 12 months, insiders at Pulmonx Corporation have bought $97,436 and sold $1.36M worth of Pulmonx Corporation stock.
On average, over the past 5 years, insiders at Pulmonx Corporation have bought $858,532 and sold $62.68M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Williamson Steven S. (PRESIDENT AND CEO) — $194,872.
The last purchase of 14,245 shares for transaction amount of $97,436 was made by Williamson Steven S. (PRESIDENT AND CEO) on 2024‑08‑20.
List of Insider Buy and Sell Transactions, Pulmonx Corporation
| 2024-10-17 | Sale | director | 20,000 0.052% | $6.52 | $130,400 | +1.40% | ||
| 2024-09-12 | Sale | director | 20,000 0.0505% | $8.09 | $161,800 | -14.30% | ||
| 2024-09-03 | Sale | CHIEF COMMERCIAL OFFICER | 4,586 0.0121% | $6.70 | $30,721 | +9.38% | ||
| 2024-09-03 | Sale | GENERAL COUNSEL | 5,765 0.0152% | $6.69 | $38,576 | +9.38% | ||
| 2024-08-20 | PRESIDENT AND CEO | 14,245 0.0358% | $6.84 | $97,436 | +4.53% | |||
| 2024-06-24 | Sale | CHIEF COMMERCIAL OFFICER | 1,184 0.0031% | $6.16 | $7,293 | +15.23% | ||
| 2024-06-03 | Sale | CHIEF COMMERCIAL OFFICER | 4,297 0.0112% | $6.97 | $29,950 | +0.65% | ||
| 2024-06-03 | Sale | GENERAL COUNSEL | 5,475 0.0142% | $6.97 | $38,161 | +0.65% | ||
| 2024-05-22 | Sale | CHIEF COMMERCIAL OFFICER | 1,184 0.003% | $8.71 | $10,313 | -22.32% | ||
| 2024-04-22 | Sale | CHIEF COMMERCIAL OFFICER | 1,184 0.0031% | $7.49 | $8,868 | -1.35% | ||
| 2024-03-22 | Sale | CHIEF COMMERCIAL OFFICER | 1,184 0.0031% | $9.36 | $11,082 | -19.09% | ||
| 2024-03-01 | Sale | PRESIDENT AND CEO | 6,954 0.0175% | $9.06 | $63,003 | -19.37% | ||
| 2024-03-01 | Sale | CHIEF COMMERCIAL OFFICER | 3,097 0.0078% | $9.06 | $28,059 | -19.37% | ||
| 2024-03-01 | Sale | GENERAL COUNSEL | 4,351 0.0109% | $9.06 | $39,420 | -19.37% | ||
| 2024-03-01 | Sale | INTERIM CFO | 1,078 0.0027% | $9.06 | $9,767 | -19.37% | ||
| 2024-02-22 | Sale | CHIEF COMMERCIAL OFFICER | 1,184 0.0037% | $14.20 | $16,813 | -35.92% | ||
| 2024-02-15 | Sale | PRESIDENT AND CEO | 20,000 0.052% | $14.60 | $292,000 | -47.09% | ||
| 2024-01-22 | Sale | CHIEF COMMERCIAL OFFICER | 1,184 0.003% | $13.13 | $15,546 | -40.55% | ||
| 2024-01-18 | Sale | PRESIDENT AND CEO | 10,000 0.026% | $12.77 | $127,700 | -37.72% | ||
| 2023-12-22 | Sale | Chief Commercial Officer | 1,184 0.0031% | $12.75 | $15,096 | -35.14% |
Insider Historical Profitability
| Williamson Steven S. | PRESIDENT AND CEO | 219531 0.5607% | $7.62 | 1 | 0 | |
| Ferrari Richard | director | 30035 0.0767% | $7.62 | 3 | 0 | +64.56% |
| Mead Dana G Jr. | director | 26315 0.0672% | $7.62 | 1 | 0 | <0.0001% |
| Melenikiotou Georgia | director | 26315 0.0672% | $7.62 | 1 | 0 | <0.0001% |
| Lynch Alissa Hsu | director | 11910 0.0304% | $7.62 | 1 | 0 | +101.97% |
Institutional Investor Ownership
| PRIMECAP Management Co | $53.2M | 14.79 | 5.74M | +1.65% | +$861,887.52 | 0.04 | |
| Fidelity Investments | $45M | 12.51 | 4.85M | +46.67% | +$14.32M | <0.01 | |
| BlackRock | $28.16M | 7.83 | 3.04M | -2.56% | -$739,718.17 | <0.01 | |
| Point72 Asset Management | $25.17M | 7 | 2.72M | +75.61% | +$10.84M | 0.04 | |
| Morgan Stanley | $24.58M | 6.83 | 2.65M | +16.36% | +$3.46M | <0.01 |